• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Emergent BioSolutions

    Cytovance Biologics

    Baxter BioPharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Emergent BioSolutions

    Flow Sciences

    Adare Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    India Report

    Indian Firms Ramp Up R&D

    Accelerating on research spend.

    Indian Firms Ramp Up R&D
    Related CONTENT
    • Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    • Highly Potent Expansions
    • High Containment & Cost Savings with Single Use Isolator Technology
    • API to ADC: A Journey Through High Potency
    • FDA Approves Boehringer’s Ofev
    S. Harachand, Contributing Editor10.15.19
    Research and development is back in the news in the Indian pharma sector after a protracted lull.

    Making a big splurge into the oncology segment, Lupin announced a licensing deal with Germany’s Boehringer Ingelheim in September to develop and commercialize one of the company’s lead MEK inhibitors.

    This class of drugs is currently approved for treating certain variants of melanoma in combination with other agents. Several MEK inhibitors are under clinical evaluation for their efficacy in different cancer types.

    Lupin’s MEK candidates have shown preclinical activity both as a single agent and in combination. In addition, they have demonstrated early clinical benefit in a small subset of patients, according to a company statement.

    The new partnership will see Lupin’s LN3794 clinically validated in combination with Boehringer’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

    The complementary mechanisms of action of KRAS inhibitors with MEK drugs results in increased anti-tumor activity keeping KRAS-driven cancers in check, based on preclinical data. According to Norbert Kraut, head of global cancer research at Boehringer Ingelheim, the drugs are expected to provide “more effective and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available.”

    The deal will bring an upfront payment of $20 million to Lupin as well as potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total value of more than $700 million.

    Meanwhile, the deal entitles Boehringer with the global rights to commercialize the drug except in India. Lupin will receive double-digit royalties on the sales of the product.

    Last December, Lupin started a similar collaboration with U.S.-headquartered AbbVie to develop and commercialize its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitors as novel treatments for hematological cancers. AbbVie licensed exclusive global rights to Lupin’s MALT1 inhibitor program. MALT1 protein is involved in the activation of T-cell and B-cell lymphocytes.

    Under the terms of the agreement, Lupin is eligible to receive total milestone payments of up to $947 million. The Mumbai-based firm has received an upfront payment of $30 million.

    The high-stakes discovery research gamble has never been a priority area for most of the Indian generic players. Of course, a few among them did venture out into the arena of discovery research with partial success.

    Interestingly, some of the leading players have suddenly wanted to accelerate their drug discovery efforts and started building a robust research pipeline, along the lines of Lupin.

    Sun Pharma’s recent tie-up with HitGen is a case in point. Sun Pharma Advanced Research Company (SPARC) entered into a pact with the Chinese biotech firm in March to pursue small molecule leads. HitGen uses a platform technology based on DNA-encoded library design, synthesis and screening to identify novel leads. The technique is found to be capable of yielding huge numbers of DNA-encoded molecules, with each compound screened against protein targets for strong binding properties.

    Diversity of compounds coupled with quick turnaround time and relatively lower costs makes HitGen’s DNA-encoded chemistry an attractive proposition to pharma companies.

    Under this collaboration, HitGen will discover novel leads for SPARC and receive upfront and milestone payments.

    Firms that do not have a direct stake in discovery research are now intensifying their pursuit in R&D, reports show.

    Aurobindo Pharma, for example, has decided to spend over 5 percent of its sales value on R&D for the current financial year 2019-20. The Hyderabad-based drug manufacturer, which raked in annual sales revenue of $2.6 billion in 2017-18, invested 4.5% of its turnover in R&D last fiscal. Aurobindo is planning to boost its biosimilar development program in addition to  formulations and API research.

    In a related development, AstraZeneca opened a development operations center in Bangalore to support clinical research in India. The center, which was opened in May, will support the development of AstraZeneca’s innovative medicines and host clinical trial experts focused on core therapeutic areas such as oncology, cardio-vascular, renal and metabolism, and respiratory, said a company release. The facility can handle 20 studies across 150 sites. 


    S. Harachand
    Contributing Editor

    S. Harachand is a pharmaceutical journalist based in Mumbai. He can be reached at harachand@gmail.com.
    Related Searches
    • API
    • astrazeneca
    • Development
    • facility
    Suggested For You
    Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    Highly Potent Expansions Highly Potent Expansions
    High Containment & Cost Savings with Single Use Isolator Technology High Containment & Cost Savings with Single Use Isolator Technology
    API to ADC: A Journey Through High Potency API to ADC: A Journey Through High Potency
    FDA Approves Boehringer’s Ofev  FDA Approves Boehringer’s Ofev
    Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center
    Alkahest Appoints Chief Business Officer Alkahest Appoints Chief Business Officer
    Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline
    Pricing Headwinds Pricing Headwinds
    20	Boehringer-Ingelheim 20 Boehringer-Ingelheim
    05	Sanofi 05 Sanofi
    Outsourcing in China: How far can it go? Outsourcing in China: How far can it go?
    11	Bristol-Myers Squibb 11 Bristol-Myers Squibb
    Boehringer, Yuhan Enter NASH Pact Boehringer, Yuhan Enter NASH Pact
    Oxford Bio Receives Boehringer Milestone Oxford Bio Receives Boehringer Milestone

    Related India Report

    • R&D
      Strategic Discovery

      Strategic Discovery

      CROs top offerings with biology skills.
      S. Harachand , Contributing Editor 10.10.18

    • Drug Delivery | Drug Discovery | R&D

      Discovery: The New Mantra

      R&D spend shoots up as firms turn research savvy
      S. Harachand, Contributing Editor 07.12.16

    • Chemistry | Drug Discovery | Methods Development | R&D | Toxicology

      Offshoring Research

      Discovery outsourcing bounces back
      S. Harachand, Contributing Editor 11.09.12


    • Biologics, Proteins, Vaccines | Biosimilars | R&D

      Move To Monoclonals

      CMOs' MAb skills in the spotlight
      S Harachand 04.04.12

    • APIs | Capsules | Chemistry | Drug Delivery | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | R&D | Toxicology

      CRAMS Rising

      Quality will benchmark growth
      S. Harachand 07.13.11

    • Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Clinical Trials | Drug Development | Methods Development | Process Development | R&D | Toxicology

      Eyeing A 'Similar' Pie

      Is a bet on cheaper bio-drugs safe?
      S. Harachand 04.29.11


    • Bioassay Development | Chemistry | Clinical Trials | Drug Development | Drug Discovery | Extractables and Leachables | Facilities | GMPs/GCPs | Methods Development | Process Development | QA/QC | R&D | Toxicology | Validation

      Advinus Speeds Through Discovery Maze

      Q&A with Dr. Rashmi H. Barbhaiya
      S. Harachand 10.08.10

    • R&D

      Springboard for Up & Coming Markets

      Indian CMOs become indispensable?
      S. Harachand 07.09.10

    • Biosimilars | Clinical Trials | R&D

      Vaccine Players on The Move

      Great potential for vaccine services
      S. Harachand 06.01.10


    • R&D

      Patents Without Exclusivity

      IP rights granted, but not protected
      S. Harachand 04.05.10

    • Chemistry | Drug Discovery | R&D | Supply Chain

      Hedging on the Emerging

      India-specific pricing bucks trend
      S. Harachand 07.18.08

    • APIs | Chemistry | Clinical Trials | Drug Development | Drug Discovery | Injectables | Process Development | R&D | Toxicology

      Discovering Partners

      R&D firms move from providing to partnering
      S. Harachand 01.17.08


    • Drug Delivery | Injectables | R&D

      Jumping on the Delivery Bandwagon

      Drug research gets NDDS-savvy
      S. Harachand 10.10.07

    • APIs | Chemistry | Injectables | R&D

      A Twist in Generics Sales

      Are Indian CMO factories the key to global forays?
      S. Harachand 09.06.07

    • Clinical Trials | R&D

      Basking in a Boom

      Salaries zoom in India's CRO  market
      S. Harachand 06.04.07

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Gelest CEO Elected to National Academy of Engineering
    PPG Appoints Tony Wu as VP, Automotive Refinish, Asia
    PPG Appoints John Bruno as VP, Investor Relations
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login